2.335

3.67% -0.095

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.335, with a volume of 82,529. It is down -3.67% in the last 24 hours and down -27.08% over the past month. Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Previous Close:

$2.43

Open:

$2.44

24h Volume:

82,529

Relative Volume:

0.07

Market Cap:

$144.01M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-1.0241

EPS:

-2.28

Net Cash Flow:

$-66.75M

1W Performance:

-17.87%

1M Performance:

-27.08%

6M Performance:

-52.90%

1Y Performance:

+4.97%

1-Day Range:

$2.3316

$2.455

1-Week Range:

$2.3397

$2.86

52-Week Range:

$2.155

$7.66

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

617-417-5868

Address

ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX	2.34	144.01M	0	-82.44M	-66.75M	-2.28
VRTX	445.32	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.78	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	584.00	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.00	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.17	24.49B	3.30B	-501.07M	1.03B	11.54

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Nov 16, 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decrease in Short Interest - MarketBeat

Nov 16, 2024

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Vestal Point Capital, LP Increases Stake in Black Diamond Therap - GuruFocus.com

Nov 14, 2024

Nov 08, 2024

What is HC Wainwright's Estimate for BDTX FY2024 Earnings? - MarketBeat

Nov 08, 2024

Wedbush Has Optimistic View of BDTX FY2024 Earnings - MarketBeat

Nov 08, 2024

Nov 06, 2024

Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 06, 2024

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

Black Diamond Therapeutics Reports Promising Q3 2024 Results - TipRanks

Nov 05, 2024

Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024

BDTXBlack Diamond Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

Nov 05, 2024

Black Diamond's BDTX-1535 Shows 42% Response Rate in Lung Cancer Trial, Reports Q3 Results | BDTX Stock News - StockTitan

Nov 05, 2024

Nov 01, 2024

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Nov 01, 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World

Nov 01, 2024

Oct 31, 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat

Oct 31, 2024

Oct 26, 2024

Foundations Investment Advisors LLC Has $445,000 Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Oct 26, 2024

Oct 16, 2024